prednisone has been researched along with Cholera Infantum in 95 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 9.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "Tetracycline was shown to be effective as an adjuvant therapy for pemphigus with low toxicity and safety." | 9.09 | Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. ( Calebotta, A; Carvalho, M; Castillo, R; González, F; Sáenz, AM, 1999) |
| "The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+)." | 5.41 | A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. ( Bazeos, A; Clark, E; de Vos, S; Feugier, P; Flinn, IW; Gasiorowski, R; Greil, R; Humphrey, K; Illés, Á; Jiang, Y; Johnson, NA; Kim, SY; Larouche, JF; Lugtenburg, PJ; Mir, F; Morschhauser, F; Patti, C; Punnoose, E; Salles, GA; Samineni, D; Sinha, A; Spielewoy, N; Trněný, M; Zelenetz, AD, 2021) |
| "To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis." | 5.14 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. ( Costello, R; Csako, G; Fleischmann, R; Goldbach-Mansky, R; Kempf, P; Kivitz, A; Lipsky, PE; Olsen, N; Pham, TH; Pucino, F; Sherrer, Y; Silverfield, J; Snyder, C; Tao, X; van der Heijde, D; Wesley, R; Wilson, M, 2009) |
| "This study clearly showed the efficacy of a short course of oral prednisone (3 days), versus a placebo, in the treatment of the functional signs of acute maxillary rhinosinusitis with severe pain in adults in addition to an appropriate antibiotic treatment." | 5.11 | [Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days]. ( Bordure, P; Coriat, F; Deslandes, B; Desmonts-Gohler, C; Dubreuil, C; Gehanno, P; Gilain, L; Jankowski, R; Klossek, JM; Serrano, E; Stoll, D, 2004) |
| "Tetracycline was shown to be effective as an adjuvant therapy for pemphigus with low toxicity and safety." | 5.09 | Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. ( Calebotta, A; Carvalho, M; Castillo, R; González, F; Sáenz, AM, 1999) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| " The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs)." | 3.96 | Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. ( Bast, A; de Jong, SMG; Drent, M; Ebner, NM; Elfferich, MDP; Jessurun, NT; Lewis, EDO; Proesmans, VLJ, 2020) |
| " Therapy with oral prednisone easily controlled her skin rash but she had profuse diarrhea that did not respond to high dose intravenous corticosteroids and denileukin diftitox." | 3.73 | Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. ( Bierbaum, W; Hamadani, M; Maqbool, F; Selby, G; Tfayli, A, 2006) |
| "A 34% response was obtained in 202 evaluable patients in the terminal phase of chronic granulocytic leukemia using combinations of hydroxyurea, 6-mercaptopurine, and corticosteroids." | 3.66 | Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. ( Cavalli, F; Coleman, M; Glidewell, O; Holland, JF; Kostinas, JE; Pajak, TF; Rai, KR; Silver, RT, 1980) |
| "To appraise the efficiency of complemental antacid administration in preventing and reducing digestive disturbances during prolonged treatment with prednisone and prednisolone, 100 patients with active rheumatoid arthritis who were maintained on combined antacid and prednisone or prednisolone therapy for periods of one year or longer, were studied clinically and roentgenographically." | 3.63 | Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone. ( BOLAND, EW, 1958) |
| "Both groups were followed for 24 months after transplantation for immunosuppressive regimen-associated and time-dependent occurrences of adverse events (AEs) and serious adverse events (SAEs)." | 2.82 | Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. ( Felipe, CR; Felix, MJ; Osmar Medina-Pestana, J; Tedesco-Silva, H, 2016) |
| "Patients were randomized to receive either intensified dosing of mycophenolate mofetil (1." | 2.76 | The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. ( Dandavino, R; Gourishankar, S; Keown, P; Kiberd, BA; Wrobel, M, 2011) |
| "Recurrences were more frequent in patients >8 years of age (OR 3." | 2.75 | Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. ( Ala-Houhala, M; Arikoski, P; Hölttä, T; Jahnukainen, T; Jauhola, O; Koskimies, O; Nuutinen, M; Ormälä, T; Rajantie, J; Ronkainen, J, 2010) |
| "There may be a reduced risk of intussusception." | 2.71 | A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. ( Huber, AM; King, J; Klassen, T; McLaine, P; Pothos, M, 2004) |
| "Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle." | 2.68 | Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. ( Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996) |
| "Seven patients with active Hodgkin's lymphoma who had relapsed 4-39 months following six or more cycles of MOPP were treated with a combination of vinblastine-bleomycin-cis-platin (VBP)." | 2.65 | Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma. ( Clamon, GH; Corder, MP; Wiesenfeld, M, 1984) |
| "To date, all available therapies for prostate cancer are plagued by adverse effects." | 2.41 | Complications of chemotherapy for prostate cancer. ( Beer, TM; Bubalo, JS, 2001) |
| "Cats treated with prednisone had a significantly longer survival time than those receiving other treatments." | 1.35 | Feline gastrointestinal eosinophilic sclerosing fibroplasia. ( Craig, LE; Flatland, B; Hardam, EE; Hertzke, DM; Moore, RR; Rohrbach, BW, 2009) |
| "Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation." | 1.35 | Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. ( Hawks, RG; Meza, JL; Post-White, JE; Sacks, N; Seibel, NL; Smith, LM; Withycombe, JS, 2009) |
| "The risk of stomach cancer was 3." | 1.35 | Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. ( Aleman, BM; Besseling, G; de Bruin, ML; de Wit, R; Gietema, JA; Hauptmann, M; Kerst, JM; Noordijk, EM; Ribot, JG; van 't Veer, MB; van den Belt-Dusebout, AW; van Leeuwen, FE, 2009) |
| "Abdominal pain was the most frequent symptom, present in 34 (87%) patients." | 1.34 | Abdominal manifestations in childhood-onset systemic lupus erythematosus. ( Bader-Meunier, B; Lemelle, I; Loirat, C; Piette, JC; Pillet, P; Quartier, P; Ranchin, B; Richer, O; Salomon, R; Ulinski, T, 2007) |
| "Progressive respiratory failure developed in a 68 year-old female who was treated with single-agent oxaliplatin for colorectal cancer." | 1.33 | Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. ( Colomer, R; Fabregat, MB; Merino, BQ; Puig, J; Soy, E; Yagüe, XH, 2005) |
| "We conclude that women with breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplantation, and that treatment with prednisone was effective." | 1.33 | Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. ( Adams, KM; Bensinger, W; Flowers, ME; Gooley, TA; Hockenbery, DM; Holmberg, L; Kikuchi, K; McDonald, GB; Schoch, HG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (50.53) | 18.7374 |
| 1990's | 14 (14.74) | 18.2507 |
| 2000's | 19 (20.00) | 29.6817 |
| 2010's | 12 (12.63) | 24.3611 |
| 2020's | 2 (2.11) | 2.80 |
| Authors | Studies |
|---|---|
| Drent, M | 1 |
| Proesmans, VLJ | 1 |
| Elfferich, MDP | 1 |
| Jessurun, NT | 1 |
| de Jong, SMG | 1 |
| Ebner, NM | 1 |
| Lewis, EDO | 1 |
| Bast, A | 1 |
| Morschhauser, F | 1 |
| Feugier, P | 1 |
| Flinn, IW | 1 |
| Gasiorowski, R | 1 |
| Greil, R | 1 |
| Illés, Á | 1 |
| Johnson, NA | 1 |
| Larouche, JF | 1 |
| Lugtenburg, PJ | 1 |
| Patti, C | 1 |
| Salles, GA | 1 |
| Trněný, M | 1 |
| de Vos, S | 1 |
| Mir, F | 1 |
| Samineni, D | 1 |
| Kim, SY | 1 |
| Jiang, Y | 1 |
| Punnoose, E | 1 |
| Sinha, A | 1 |
| Clark, E | 1 |
| Spielewoy, N | 1 |
| Humphrey, K | 1 |
| Bazeos, A | 1 |
| Zelenetz, AD | 1 |
| Stein, CA | 1 |
| Levin, R | 1 |
| Given, R | 1 |
| Higano, CS | 1 |
| Nemeth, P | 1 |
| Bosch, B | 1 |
| Chapas-Reed, J | 1 |
| Dreicer, R | 1 |
| Thapa, K | 1 |
| Romo, ML | 1 |
| Carpio, A | 1 |
| Leslie, D | 1 |
| Andrews, H | 1 |
| Hauser, WA | 1 |
| Kelvin, EA | 1 |
| Reagan, KL | 1 |
| Marks, SL | 1 |
| Pesavento, PA | 1 |
| Della Maggiore, A | 1 |
| Zhu, BY | 1 |
| Grooters, AM | 1 |
| Oerlemans, S | 1 |
| Issa, DE | 1 |
| van den Broek, EC | 1 |
| Nijziel, MR | 1 |
| Coebergh, JW | 1 |
| Huijgens, PC | 1 |
| Mols, F | 1 |
| van de Poll-Franse, LV | 1 |
| Takashima, S | 1 |
| Eto, T | 1 |
| Shiratsuchi, M | 1 |
| Hidaka, M | 1 |
| Mori, Y | 1 |
| Kato, K | 1 |
| Kamezaki, K | 1 |
| Oku, S | 1 |
| Henzan, H | 1 |
| Takase, K | 1 |
| Matsushima, T | 1 |
| Takenaka, K | 1 |
| Iwasaki, H | 1 |
| Miyamoto, T | 1 |
| Akashi, K | 1 |
| Teshima, T | 1 |
| Cohen, JB | 1 |
| Switchenko, JM | 1 |
| Koff, JL | 1 |
| Sinha, R | 1 |
| Kaufman, JL | 1 |
| Khoury, HJ | 1 |
| Bumpers, N | 1 |
| Colbert, A | 1 |
| Hutchison-Rzepka, A | 1 |
| Nastoupil, LJ | 1 |
| Heffner, LT | 1 |
| Langston, AA | 1 |
| Lechowicz, MJ | 1 |
| Lonial, S | 1 |
| Flowers, CR | 1 |
| Felix, MJ | 1 |
| Felipe, CR | 1 |
| Tedesco-Silva, H | 1 |
| Osmar Medina-Pestana, J | 1 |
| Klair, JS | 1 |
| Girotra, M | 1 |
| Hutchins, LF | 1 |
| Caradine, KD | 1 |
| Aduli, F | 1 |
| Garcia-Saenz-de-Sicilia, M | 1 |
| Craig, LE | 1 |
| Hardam, EE | 1 |
| Hertzke, DM | 1 |
| Flatland, B | 1 |
| Rohrbach, BW | 1 |
| Moore, RR | 1 |
| Goldbach-Mansky, R | 1 |
| Wilson, M | 1 |
| Fleischmann, R | 1 |
| Olsen, N | 1 |
| Silverfield, J | 1 |
| Kempf, P | 1 |
| Kivitz, A | 1 |
| Sherrer, Y | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Costello, R | 1 |
| Pham, TH | 1 |
| Snyder, C | 1 |
| van der Heijde, D | 1 |
| Tao, X | 1 |
| Wesley, R | 1 |
| Lipsky, PE | 1 |
| Withycombe, JS | 1 |
| Post-White, JE | 1 |
| Meza, JL | 1 |
| Hawks, RG | 1 |
| Smith, LM | 1 |
| Sacks, N | 1 |
| Seibel, NL | 1 |
| van den Belt-Dusebout, AW | 1 |
| Aleman, BM | 1 |
| Besseling, G | 1 |
| de Bruin, ML | 1 |
| Hauptmann, M | 1 |
| van 't Veer, MB | 1 |
| de Wit, R | 1 |
| Ribot, JG | 1 |
| Noordijk, EM | 1 |
| Kerst, JM | 1 |
| Gietema, JA | 1 |
| van Leeuwen, FE | 1 |
| Jauhola, O | 1 |
| Ronkainen, J | 1 |
| Koskimies, O | 1 |
| Ala-Houhala, M | 1 |
| Arikoski, P | 1 |
| Hölttä, T | 1 |
| Jahnukainen, T | 1 |
| Rajantie, J | 1 |
| Ormälä, T | 1 |
| Nuutinen, M | 1 |
| Kiberd, BA | 1 |
| Wrobel, M | 1 |
| Dandavino, R | 1 |
| Keown, P | 1 |
| Gourishankar, S | 1 |
| Pan, A | 1 |
| Doyle, T | 1 |
| Schlup, M | 1 |
| Lubcke, R | 1 |
| Schultz, M | 1 |
| Munson, JC | 1 |
| Wahl, PM | 1 |
| Daniel, G | 1 |
| Kimmel, SE | 1 |
| Hennessy, S | 1 |
| Barlam, TF | 1 |
| McCloud, E | 1 |
| VESIN, P | 1 |
| DORDICK, JR | 1 |
| FELDER, SL | 1 |
| POLANSKY, F | 1 |
| GEFFEN, A | 1 |
| STOLZER, BL | 1 |
| BARR, JH | 1 |
| EISENBEIS, CH | 1 |
| WECHSLER, RL | 1 |
| MARGOLIS, HM | 1 |
| BONFILS, S | 1 |
| BARATGIN, B | 1 |
| ROSSI, G | 1 |
| LAMBLING, A | 1 |
| BOLAND, EW | 1 |
| BRAUCH, F | 1 |
| EWE, K | 1 |
| POINT, WW | 1 |
| Klossek, JM | 1 |
| Desmonts-Gohler, C | 1 |
| Deslandes, B | 1 |
| Coriat, F | 1 |
| Bordure, P | 1 |
| Dubreuil, C | 1 |
| Gehanno, P | 1 |
| Gilain, L | 1 |
| Jankowski, R | 1 |
| Serrano, E | 1 |
| Stoll, D | 1 |
| Huber, AM | 1 |
| King, J | 1 |
| McLaine, P | 1 |
| Klassen, T | 1 |
| Pothos, M | 1 |
| Dogan, S | 1 |
| Beyazit, Y | 1 |
| Shorbagi, A | 1 |
| Köklü, S | 1 |
| Ustunel, S | 1 |
| Guler, N | 1 |
| Uner, A | 1 |
| Yagüe, XH | 1 |
| Soy, E | 1 |
| Merino, BQ | 1 |
| Puig, J | 1 |
| Fabregat, MB | 1 |
| Colomer, R | 1 |
| Holmberg, L | 1 |
| Kikuchi, K | 1 |
| Gooley, TA | 1 |
| Adams, KM | 1 |
| Hockenbery, DM | 2 |
| Flowers, ME | 1 |
| Schoch, HG | 1 |
| Bensinger, W | 1 |
| McDonald, GB | 2 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Richer, O | 1 |
| Ulinski, T | 1 |
| Lemelle, I | 1 |
| Ranchin, B | 1 |
| Loirat, C | 1 |
| Piette, JC | 2 |
| Pillet, P | 1 |
| Quartier, P | 1 |
| Salomon, R | 1 |
| Bader-Meunier, B | 1 |
| Tfayli, A | 1 |
| Selby, G | 1 |
| Maqbool, F | 1 |
| Bierbaum, W | 1 |
| Hamadani, M | 1 |
| Cruickshank, S | 1 |
| Rodell, TC | 1 |
| Gooley, T | 1 |
| Schuening, F | 1 |
| Rowley, S | 1 |
| David, D | 1 |
| Brunvand, M | 1 |
| Berryman, B | 1 |
| Abhyankar, S | 1 |
| Bouvier, M | 1 |
| Chan, JW | 1 |
| Mateos, MV | 1 |
| Hernández, JM | 1 |
| Hernández, MT | 1 |
| Gutiérrez, NC | 1 |
| Palomera, L | 1 |
| Fuertes, M | 1 |
| Garcia-Sanchez, P | 1 |
| Lahuerta, JJ | 1 |
| de la Rubia, J | 1 |
| Terol, MJ | 1 |
| Sureda, A | 1 |
| Bargay, J | 1 |
| Ribas, P | 1 |
| Alegre, A | 1 |
| de Arriba, F | 1 |
| Oriol, A | 1 |
| Carrera, D | 1 |
| García-Laraña, J | 1 |
| García-Sanz, R | 1 |
| Bladé, J | 1 |
| Prósper, F | 1 |
| Mateo, G | 1 |
| Esseltine, DL | 1 |
| van de Velde, H | 1 |
| San Miguel, JF | 1 |
| Bakemeier, RF | 1 |
| Anderson, JR | 1 |
| Costello, W | 1 |
| Rosner, G | 1 |
| Horton, J | 1 |
| Glick, JH | 1 |
| Hines, JD | 1 |
| Berard, CW | 1 |
| DeVita, VT | 1 |
| Corder, MP | 1 |
| Clamon, GH | 1 |
| Wiesenfeld, M | 1 |
| Quarre, JP | 1 |
| Ligny, G | 1 |
| Lardinois, J | 1 |
| Dehout, F | 1 |
| Meunier, R | 1 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Pajak, TF | 1 |
| Cavalli, F | 1 |
| Rai, KR | 1 |
| Kostinas, JE | 1 |
| Glidewell, O | 1 |
| Holland, JF | 1 |
| Maggiolo, P | 1 |
| Pfau, J | 1 |
| Klinger, J | 1 |
| ReMine, SG | 1 |
| McIlrath, DC | 1 |
| Guillevin, L | 1 |
| Lhote, F | 1 |
| Gallais, V | 1 |
| Jarrousse, B | 1 |
| Royer, I | 1 |
| Gayraud, M | 1 |
| Benichou, J | 1 |
| Fryer, JP | 1 |
| Granger, DK | 1 |
| Leventhal, JR | 1 |
| Gillingham, K | 1 |
| Najarian, JS | 1 |
| Matas, AJ | 1 |
| Jaffe, R | 1 |
| Wollman, MR | 1 |
| Kocoshis, S | 1 |
| Penchansky, L | 1 |
| Gilbert-Barness, E | 1 |
| Chisesi, T | 1 |
| Hoelzer, D | 1 |
| Ludwig, WD | 1 |
| Thiel, E | 1 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Fonatsch, C | 1 |
| Rieder, H | 1 |
| Heil, G | 1 |
| Heinze, B | 1 |
| Arnold, R | 1 |
| Hossfeld, D | 1 |
| Büchner, T | 1 |
| Koch, P | 1 |
| Freund, M | 1 |
| Hiddemann, W | 1 |
| Maschmeyer, G | 1 |
| Heyll, A | 1 |
| Aul, C | 1 |
| Faak, T | 1 |
| Kuse, R | 1 |
| Ittel, TH | 1 |
| Gramatzki, M | 1 |
| Diedrich, H | 1 |
| Kolbe, K | 1 |
| Fuhr, HG | 1 |
| Fischer, K | 1 |
| Schadeck-Gressel, C | 1 |
| Weiss, A | 1 |
| Strohscheer, I | 1 |
| Metzner, B | 1 |
| Fabry, U | 1 |
| Gökbuget, N | 1 |
| Völkers, B | 1 |
| Messerer, D | 1 |
| Uberla, K | 1 |
| Shaklai, S | 1 |
| Bairey, O | 1 |
| Blickstein, D | 1 |
| Prokocimer, M | 1 |
| Hadar, H | 1 |
| Lahav, M | 1 |
| Sulkes, J | 1 |
| Shaklai, M | 1 |
| Bellesi, G | 1 |
| Rigacci, L | 1 |
| Alterini, R | 1 |
| Bernardi, F | 1 |
| Stefanacci, S | 1 |
| Innocenti, F | 1 |
| Fusco, II | 1 |
| Longo, G | 1 |
| Di Lollo, S | 1 |
| Ferrini, PR | 1 |
| Comenzo, RL | 1 |
| Vosburgh, E | 1 |
| Simms, RW | 1 |
| Bergethon, P | 1 |
| Sarnacki, D | 1 |
| Finn, K | 1 |
| Dubrey, S | 1 |
| Faller, DV | 1 |
| Wright, DG | 1 |
| Falk, RH | 1 |
| Skinner, M | 1 |
| Mejía-Arangure, JM | 1 |
| Fajardo-Gutíerrez, A | 1 |
| Bernáldez-Ríos, R | 1 |
| Rodríguez-Zepeda, MC | 1 |
| Espinoza-Hernández, L | 1 |
| Martínez-García, MC | 1 |
| Gruessner, RW | 1 |
| Calebotta, A | 1 |
| Sáenz, AM | 1 |
| González, F | 1 |
| Carvalho, M | 1 |
| Castillo, R | 1 |
| Beer, TM | 1 |
| Bubalo, JS | 1 |
| Emery, H | 1 |
| Larter, W | 1 |
| Schaller, JG | 1 |
| Tytgat, GN | 1 |
| Archibald, SD | 1 |
| Jirsch, DW | 1 |
| Bear, RA | 1 |
| Eigler, FW | 1 |
| Dostal, G | 1 |
| Beersiek, F | 1 |
| Medrano, J | 1 |
| Bock, KD | 1 |
| Hartmann, H | 1 |
| Kuwert, EK | 1 |
| Fries, JF | 1 |
| Williams, CA | 1 |
| Bloch, DA | 1 |
| Michel, BA | 1 |
| Egeler, RM | 1 |
| Schipper, ME | 1 |
| Heymans, HS | 1 |
| Farris, BK | 1 |
| Pickard, DJ | 1 |
| McCauley, RL | 1 |
| Johnston, MR | 1 |
| Fauci, AS | 1 |
| Bernstein, DI | 1 |
| Bernstein, IL | 1 |
| Bodenheimer, SS | 1 |
| Pietrusko, RG | 1 |
| Wechsler, B | 1 |
| Le Thi Huong, Du | 1 |
| Langlois, P | 1 |
| Baumer, R | 1 |
| Ghesquiere, F | 1 |
| Herson, S | 1 |
| Godeau, P | 1 |
| Siegel, RR | 1 |
| Kühn, RA | 1 |
| Hansen, C | 1 |
| Müller, W | 1 |
| Arvanitakis, C | 1 |
| Manier, JW | 1 |
| Salmon, PR | 1 |
| Paulley, JW | 1 |
| Akoun, G | 1 |
| Vachon, J | 1 |
| Muon, N | 1 |
| Brocard, H | 1 |
| Engquist, A | 1 |
| Backer, OG | 1 |
| Jarnum, S | 1 |
| Betts, RF | 1 |
| Douglas, RG | 1 |
| Pabico, RC | 1 |
| Talley, TE | 1 |
| Yakub, YN | 1 |
| Freeman, RB | 1 |
| Storti, E | 1 |
| Fontana, G | 1 |
| Sherman, NJ | 1 |
| Williams, K | 1 |
| Woolley, MM | 1 |
| Abbona, C | 1 |
| Marugo, M | 1 |
| Berretti, A | 1 |
| Diethelm, AG | 1 |
| Aldrete, JS | 1 |
| Shaw, JF | 1 |
| Cobbs, CG | 1 |
| Hartley, MW | 1 |
| Sterling, WA | 1 |
| Morgan, JM | 1 |
| Harket, R | 1 |
| Fausa, O | 1 |
| Nygaard, K | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Hahn, RG | 1 |
| Rothschild, MA | 1 |
| Oratz, M | 1 |
| Schreiber, SS | 1 |
| Riis, P | 1 |
| Bontoux, D | 1 |
| Wüstenberg, PW | 1 |
| Vetter, D | 1 |
| Zaruba, K | 1 |
| Scheitlin, W | 1 |
| Hardisty, RM | 1 |
| McElwain, TJ | 1 |
| Darby, CW | 1 |
| Seghal, VN | 1 |
| Scheibe, O | 1 |
| Hall, TC | 1 |
| Choi, OS | 1 |
| Abadi, A | 1 |
| Krant, MJ | 1 |
| Henrard, JC | 1 |
| Gambetta, OV | 1 |
| Simkin, PA | 1 |
| Healey, LA | 1 |
| Kaplan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ib/II, Open-Label Study Evaluating the Safety, Efficacy and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell[NCT02055820] | Phase 1/Phase 2 | 267 participants (Actual) | Interventional | 2013-11-17 | Completed | ||
| A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179] | Phase 1/Phase 2 | 37 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection[NCT01015391] | 100 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection[NCT01666990] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study[NCT00002812] | Phase 3 | 2,078 participants (Actual) | Interventional | 1996-09-30 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastroin[NCT00926575] | Phase 3 | 140 participants (Actual) | Interventional | 2009-10-31 | Terminated (stopped due to An independent Data Safety Monitoring Board recommended the study be stopped due to futility) | ||
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 32.1 |
Cmax was determined using the post-dose Doxorubicin plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 1260 |
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 326 |
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: >/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions. (NCT02055820)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 85.71 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 87.50 |
| Venetoclax 800mg + R-CHOP | 66.67 |
| Venetoclax + R-CHOP 800 mg Phase II | 88.99 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 75.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to NCT02055820)
Timeframe: Baseline up to end of treatment (approx. 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 37.4 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 66.7 |
"Objective Response defined as PR (partial response) or CR (complete response) at end of treatment.~CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.~PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR" (NCT02055820)
Timeframe: Baseline to end of treatment (up to approximately 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 81.5 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 68.2 |
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 173 |
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2. (NCT02055820)
Timeframe: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 26.1 |
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade >/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs. (NCT02055820)
Timeframe: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
| Intervention | Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 1 |
| Venetoclax 400 mg + R-CHOP | 0 |
| Venetoclax 600 mg + R-CHOP | 1 |
| Venetoclax 800mg + R-CHOP | 0 |
| Venetoclax 200mg + G-CHOP | 2 |
| Venetoclax 400mg + G-CHOP | 1 |
| Venetoclax 600mg + G-CHOP | 1 |
| Venetoclax 800 mg + G-CHOP A | 0 |
| Venetoclax 800 mg + G-CHOP B | 0 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02055820)
Timeframe: Baseline up to approximately 36 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 100.00 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 100.00 |
| Venetoclax 800mg + R-CHOP | 100.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 99.0 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 100.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
"AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as hour*micrograms per milliliter (hr*mcg/mL)" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) |
|---|---|
| Venetoclax 800mg + R-CHOP | .66 |
| Venetoclax 200 mg + R-CHOP | 2.51 |
| Venetoclax 400 mg + R-CHOP | 3.87 |
| Venetoclax 600 mg + R-CHOP | 3.70 |
| Venetoclax + R-CHOP 800 mg | 4.51 |
| Venetoclax 200mg + G-CHOP | 2.55 |
| Venetoclax 400mg + G-CHOP | 4.33 |
| Venetoclax 600mg + G-CHOP | 5.13 |
| Venetoclax + G-CHOP 800mg | 6.20 |
"Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as micrograms per milliliter" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Ug/ML (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | .09 |
| Venetoclax 200 mg + R-CHOP | .58 |
| Venetoclax 400 mg + R-CHOP | .92 |
| Venetoclax 600 mg + R-CHOP | .85 |
| Venetoclax 800mg + R-CHOP | 1.15 |
| Venetoclax 200mg + G-CHOP | .52 |
| Venetoclax 400mg + G-CHOP | 1.26 |
| Venetoclax 600mg + G-CHOP | 1.00 |
| Venetoclax + G-CHOP 800 mg | 1.54 |
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 0.0714 |
| Venetoclax 200 mg + R-CHOP | 0.522 |
| Venetoclax 400 mg + R-CHOP | 0.253 |
| Venetoclax 600 mg + R-CHOP | 0.387 |
| Venetoclax 800mg + R-CHOP | 0.640 |
| Venetoclax 200mg + G-CHOP | 0.134 |
| Venetoclax 400mg + G-CHOP | 0.395 |
| Venetoclax 600mg + G-CHOP | 0.612 |
| Venetoclax + G-CHOP 800 mg | 0.628 |
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Hour (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 4.0 |
| Venetoclax 200 mg + R-CHOP | 4.59 |
| Venetoclax 400 mg + R-CHOP | 6.50 |
| Venetoclax 600 mg + R-CHOP | 5.52 |
| Venetoclax 800mg + R-CHOP | 5.53 |
| Venetoclax 200mg + G-CHOP | 5.72 |
| Venetoclax 400mg + G-CHOP | 6.56 |
| Venetoclax 600mg + G-CHOP | 5.30 |
| Venetoclax + G-CHOP 800 mg | 5.79 |
Cmax was determined using the post-dose Vincristine plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 54.0 |
AUC was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 195 | 184 |
Cmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Ng/ML (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 49.9 | 43.2 |
Tmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Hour (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 2.19 | 3.80 |
Dose intensity was categorized as < 80%, 80% to < 85%, 85% to < 90%, or >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of Partcipants (Number) | |||
|---|---|---|---|---|
| <80% | 80-<85% | 85-<90% | >=90% | |
| Venetoclax + G-CHOP 800 mg | 83.3 | 0.00 | 16.7 | 0.00 |
| Venetoclax + G-CHOP 800mg B | 100.0 | 0.00 | 0.00 | 0.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 26.0 | 3.4 | 2.9 | 67.6 |
| Venetoclax 200 mg + R-CHOP | 71.4 | 0.00 | 0.00 | 28.6 |
| Venetoclax 200mg + G-CHOP | 100.00 | 0.00 | 0.00 | 0.00 |
| Venetoclax 400 mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
| Venetoclax 400mg + G-CHOP | 14.3 | 14.3 | 0.00 | 71.4 |
| Venetoclax 600 mg + R-CHOP | 12.5 | 12.5 | 12.5 | 62.5 |
| Venetoclax 600mg + G-CHOP | 50.0 | 16.7 | 0.00 | 33.3 |
| Venetoclax 800mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
Maintenance of relative dose intensity was defined as a dose intensity of >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cyclophosphamide | Doxorubicin | Vincristine | Prednisone | |
| Venetoclax + R-CHOP Arm | 89.5 | 88.6 | 86.6 | 87.4 |
| Venetoclax 600mg + G-CHOP | 77.4 | 77.4 | 78.1 | 81.3 |
INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| MTD of Bortezomib With Vincristine Capped at 1.5 mg | 1.62 |
Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (ORR) | |
| Phase I: Induction | 13 | 6 | 19 |
| Phase II: Maintenance | 19 | 10 | 29 |
8 reviews available for prednisone and Cholera Infantum
| Article | Year |
|---|---|
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Pathological cases of the month. Langerhans' cell histiocytosis with gastrointestinal involvement.
Topics: Biopsy; Dermatitis, Exfoliative; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Gastrointes | 1993 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Ga | 2001 |
[Corticosteroids in gastroenterology].
Topics: Adrenal Cortex Hormones; Burns, Chemical; Celiac Disease; Chronic Disease; Colitis, Ulcerative; Croh | 1978 |
Gastrointestinal involvement in Langerhans' cell histiocytosis (Histiocytosis X): a clinical report of three cases.
Topics: Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Histiocy | 1990 |
Serum albumin.
Topics: Albumins; Animals; Carbon Isotopes; Chromium Isotopes; Cortisone; DNA; Edema; Gastrointestinal Disea | 1969 |
Glucocorticoids in gastro-enterology.
Topics: Adult; Betamethasone; Celiac Disease; Colitis, Ulcerative; Cortisone; Crohn Disease; Female; Gastroi | 1969 |
[The hypoglycemia syndrome].
Topics: Alloxan; Angiography; Antibiotics, Antineoplastic; Blood Glucose; Diagnosis, Differential; Diazoxide | 1970 |
24 trials available for prednisone and Cholera Infantum
| Article | Year |
|---|---|
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2021 |
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastro | 2018 |
The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.
Topics: Administration, Oral; Albendazole; Animals; Anthelmintics; Double-Blind Method; Drug Administration | 2018 |
The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group.
Topics: Adult; Aged; Beclomethasone; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Drug | 2014 |
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-F | 2015 |
Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Topics: Adult; Brazil; Calcineurin Inhibitors; Drug Eruptions; Drug Monitoring; Drug Therapy, Combination; F | 2016 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Epidemiologic Methods; Female; Gastrointestinal D | 2010 |
The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.
Topics: Area Under Curve; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal | 2011 |
[Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days].
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-In | 2004 |
A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383].
Topics: Abdominal Pain; Administration, Oral; Child; Child, Preschool; Double-Blind Method; Female; Gastroin | 2004 |
A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Child; Fema | 2007 |
Mycophenolate mofetil for ocular myasthenia.
Topics: Adult; Autoantibodies; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Immu | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic | 2008 |
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Clinical Trials | 1984 |
Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topi | 1984 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; | 1993 |
Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 1996 |
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Topics: Adult; Amyloidosis; Cardiomyopathies; Feasibility Studies; Female; Follow-Up Studies; Gastrointestin | 1996 |
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Case-Control Studies; Cy | 1997 |
Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Chemotherapy, Adjuvant; Drug Therapy, Combination; Femal | 1999 |
[Therapeutic value of the combination of a corticosteroid (prednisone) with a gastroprotective substance (xylamide)].
Topics: Adult; Aged; Amides; Arthritis, Rheumatoid; Bronchitis; Clinical Trials as Topic; Drug Combinations; | 1972 |
[Gastric protection with sulfated polysaccharides. Study during anti-inflammatory treatment].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Drug Antagonism; Drug T | 1971 |
63 other studies available for prednisone and Cholera Infantum
| Article | Year |
|---|---|
Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis.
Topics: Adult; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointes | 2020 |
Successful management of 3 dogs with colonic pythiosis using itraconzaole, terbinafine, and prednisone.
Topics: Animals; Anti-Inflammatory Agents; Antifungal Agents; Colon; Dog Diseases; Dogs; Gastrointestinal Di | 2019 |
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Colitis; Female; Gastrointestin | 2016 |
Feline gastrointestinal eosinophilic sclerosing fibroplasia.
Topics: Animals; Cat Diseases; Cats; Eosinophilia; Fibrosis; Gastrointestinal Diseases; Immunohistochemistry | 2009 |
The Chinese herbal remedy Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; D | 2009 |
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind | 2009 |
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Combine | 2009 |
Unusual manifestation of Erdheim-Chester disease.
Topics: Aged; Diagnosis, Differential; Erdheim-Chester Disease; Gastrointestinal Diseases; Humans; Hydrocort | 2011 |
Factors associated with the initiation of proton pump inhibitors in corticosteroid users.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Databases, Factual; Dose-Respo | 2012 |
Severe gastrointestinal illness associated with olestra ingestion.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Chil | 2003 |
[Digestive complications of delta-cortisone therapy].
Topics: Gastrointestinal Diseases; Humans; Prednisone | 1957 |
Gastrointestinal side-effects related to prednisone; preliminary observations.
Topics: Gastrointestinal Diseases; Humans; Prednisolone; Prednisone | 1957 |
Prednisone and prednisolone therapy in rheumatoid arthritis; clinical evaluation, with emphasis on gastrointestinal manifestations in one hundred fifty-six patients observed for periods of four to fourteen months.
Topics: Arthritis; Arthritis, Rheumatoid; Gastrointestinal Diseases; Peptic Ulcer; Prednisolone; Prednisone | 1957 |
[The mechanism of gastroduodenal complications induced by treatment with corticoids (cortisone and prednisone)].
Topics: Adrenal Cortex Hormones; Cortisone; Gastrointestinal Diseases; Humans; Prednisone | 1958 |
Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone.
Topics: Aluminum Hydroxide; Antacids; Arthritis, Rheumatoid; Gastrointestinal Diseases; Humans; Prednisolone | 1958 |
[Gastrointestinal complications occurring in modern antirheumatic treatment].
Topics: Antirheumatic Agents; Cortisone; Gastrointestinal Diseases; Peptic Ulcer; Phenylbutazone; Prednisone | 1959 |
[TREATMENT OF EXUDATIVE ENTEROPATHIES].
Topics: Drug Therapy; Gastrointestinal Diseases; Humans; Hypoproteinemia; Prednisone; Protein-Losing Enterop | 1965 |
GASTROINTESTINAL DISORDERS IN ADOLESCENTS.
Topics: Adolescent; Cecal Neoplasms; Colitis; Colitis, Ulcerative; Diagnosis; Diet; Diet Therapy; Drug Thera | 1965 |
Gastrointestinal involvement in POEMS syndrome: a novel clinical manifestation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gastro | 2005 |
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chemothera | 2005 |
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.
Topics: Adult; Anti-Inflammatory Agents; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematopoi | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Abdominal manifestations in childhood-onset systemic lupus erythematosus.
Topics: Abdomen, Acute; Abdominal Pain; Adolescent; Ascites; Biomarkers; C-Reactive Protein; Child; Child, P | 2007 |
Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease.
Topics: Administration, Oral; Antineoplastic Agents; Diarrhea; Diphtheria Toxin; Drug Resistance; Female; Ga | 2006 |
[2 case reports of Schönlein-Henoch purpura].
Topics: Adult; Gastrointestinal Diseases; Glomerulosclerosis, Focal Segmental; Humans; IgA Vasculitis; Joint | 1983 |
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.
Topics: Daunorubicin; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Human | 1980 |
[Gastroduodenal lesions in rheumatoid arthritis, mesenchymopathies and other rheumatisms. Endoscopic study].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Female; Gastrointestinal Diseases; Gastros | 1982 |
Bowel perforation in steroid-treated patients.
Topics: Adult; Aged; Colonic Diseases; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; | 1980 |
Gastrointestinal tract involvement in polyarteritis nodosa and Churg-Strauss syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Churg-Strauss Syndrome; Cyclophosphamide | 1995 |
Steroid-related complications in the cyclosporine era.
Topics: Adult; Age Factors; Bacterial Infections; Bone Diseases; Cataract; Cyclosporine; Diabetes Mellitus; | 1994 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Nutritional state alterations in children with acute lymphoblastic leukemia during induction and consolidation of chemotherapy.
Topics: Adolescent; Anthropometry; Antineoplastic Combined Chemotherapy Protocols; Arm; Asparaginase; Body C | 1997 |
Henoch-Schönlein vasculitis.
Topics: Follow-Up Studies; Gastrointestinal Diseases; Humans; IgA Vasculitis; Joint Diseases; Prednisone; Pr | 1977 |
Gastrointestinal complications of renal transplantation. 1. The upper gastrointestinal tract.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cadaver; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointe | 1978 |
[Results of 200 renal transplantations (author's transl)].
Topics: Azathioprine; Gastrointestinal Diseases; Humans; Kidney Transplantation; Postoperative Complications | 1979 |
Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1991 |
Bilateral postinfectious optic neuritis and intravenous steroid therapy in children.
Topics: Adolescent; Child; Child, Preschool; Female; Gastrointestinal Diseases; Humans; Magnetic Resonance I | 1990 |
Surgical aspects of systemic necrotizing vasculitis.
Topics: Abdomen; Adolescent; Adult; Aged; Angiography; Biopsy; Cyclophosphamide; Drug Administration Schedul | 1985 |
An open study of auranofin in the treatment of steroid-dependent asthma.
Topics: Adult; Asthma; Auranofin; Female; Gastrointestinal Diseases; Humans; Immunity, Cellular; Male; Metha | 1988 |
[Corticotherapy and surgery. Apropos of 73 cases].
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; H | 1985 |
Gastrointestinal complications after renal transplantation.
Topics: Antacids; Gastrointestinal Diseases; Humans; Kidney Transplantation; Prednisolone; Prednisone; Trans | 1972 |
[Clinical aspects of virus influenza. Course and complications in a two-year patient material].
Topics: Adolescent; Adult; Age Factors; Aged; Aminopyrine; Anti-Bacterial Agents; Child; Electrocardiography | 1973 |
Crohn's disease: a clinical study of 75 patients.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Child; Crohn Disease; Female; Fol | 1973 |
Eosinophilic granuloma of the gastro-intestinal tract.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Eosinophilic Granuloma; Gastrointestinal Diseases; H | 1967 |
[Prescription of corticotherapy on alternate days for long periods].
Topics: 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenocortical Hyperfunct | 1968 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |
Incidence of postoperative complications in patients subjected to surgery under steroid cover.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Female; Gastrointestinal Diseases; Genital Dis | 1974 |
Shedding patterns of herpes simplex virus and cytomegalovirus among chronic dialysis patients.
Topics: Biopsy; Blood; Cytomegalovirus; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; | 1972 |
[Use of L-asparaginase in therapy with special reference to acute lymphatic leukemia].
Topics: Adolescent; Adult; Asparaginase; Autoimmune Diseases; Blood Platelet Disorders; Child; Child, Presch | 1972 |
Surgical complications in the patient with leukemia.
Topics: Adolescent; Appendicitis; Child; Child, Preschool; Gastrointestinal Diseases; Humans; Hypersplenism; | 1973 |
Clinical evaluation of equine antithymocyte globulin in recipients of renal allografts: Analysis of survival, renal function, rejection, histocompatibility, and complications.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Azathioprine; Bone Diseases; Child; Evaluation Stu | 1974 |
Progressive occlusive endarteritis. A case report.
Topics: Adult; Arterial Occlusive Diseases; Arteries; Autopsy; Azathioprine; Coronary Vessels; Endarteritis; | 1973 |
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua | 1974 |
[Gastrointestinal complications and gastric juice secretion before and after kidney transplantation].
Topics: Adult; Esophageal Diseases; Female; Gastric Juice; Gastrointestinal Diseases; Humans; Kidney Disease | 1971 |
Vincristine and prednisone for the induction of remissions in acute childhood leukaemia.
Topics: Acute Disease; Alopecia; Child; Child, Preschool; Drug Synergism; Gastrointestinal Diseases; Humans; | 1969 |
[Histological report No. 223. Degos syndrome (papulosis atrophicans maligna)].
Topics: Adult; Arteritis; Fibromyalgia; Gastrointestinal Diseases; Humans; India; Intestinal Diseases; Male; | 1969 |
[Dangerous complications of antirheumatic therapy].
Topics: Aged; Anti-Inflammatory Agents; Gastrointestinal Diseases; Humans; Male; Prednisone; Rheumatic Disea | 1970 |
High-dose corticoid therapy in Hodgkin's disease and other lymphomas.
Topics: Adolescent; Adult; Aged; Cortisone; Diabetes Mellitus; Female; Gastrointestinal Diseases; Hodgkin Di | 1967 |
[Current antalgic anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents; Betamethasone; Cortisone; Dexamethasone; Endocrine System Diseases; Eye Di | 1970 |
[Corticosteroids and moniliasis].
Topics: Bronchopneumonia; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Female; Gastrointestinal D | 1967 |
Giant cell arteritis with polymyalgia rheumatica, loss of vision, and abdominal symptoms occurring during a four year course.
Topics: Aged; Blindness; Blood Sedimentation; Diarrhea; Gastrointestinal Diseases; Giant Cell Arteritis; Hum | 1969 |
Corticosteroids in general medicine.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Collagen Diseases; Gastrointestinal Diseases; Hemato | 1966 |